Candido, S.; Salemi, R.; Piccinin, S.; Falzone, L.; Libra, M.
The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K–Akt Pathways. Pharmaceutics 2022, 14, 590.
https://doi.org/10.3390/pharmaceutics14030590
AMA Style
Candido S, Salemi R, Piccinin S, Falzone L, Libra M.
The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K–Akt Pathways. Pharmaceutics. 2022; 14(3):590.
https://doi.org/10.3390/pharmaceutics14030590
Chicago/Turabian Style
Candido, Saverio, Rossella Salemi, Sara Piccinin, Luca Falzone, and Massimo Libra.
2022. "The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K–Akt Pathways" Pharmaceutics 14, no. 3: 590.
https://doi.org/10.3390/pharmaceutics14030590
APA Style
Candido, S., Salemi, R., Piccinin, S., Falzone, L., & Libra, M.
(2022). The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K–Akt Pathways. Pharmaceutics, 14(3), 590.
https://doi.org/10.3390/pharmaceutics14030590